| Angioedemas, Hereditary
Haegarda vs Ruconest
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Haegarda vs Ruconest with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRuconest has a higher rate of injection site reactions vs Haegarda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ruconest but not Haegarda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Haegarda
Ruconest
At A Glance
SC injection
Twice weekly
C1-esterase inhibitor
IV injection
As needed (up to 2 doses/24 hours)
C1 esterase inhibitor (recombinant)
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 60 IU/kg by subcutaneous injection twice weekly (every 3 or 4 days); self- or caregiver-administered after reconstitution.
Angioedemas, Hereditary 50 U/kg IV (max 4200 U) by slow intravenous injection over approximately 5 minutes; a second dose at the same level may be given if symptoms persist; no more than 2 doses within 24 hours.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or any excipient
- History of allergy to rabbits or rabbit-derived products
- History of life-threatening immediate hypersensitivity reactions to C1 esterase inhibitor preparations, including anaphylaxis
Adverse Reactions
Most common (>4%) injection site reactions, hypersensitivity, nasopharyngitis, dizziness
Most common (>=2%) Headache, nausea, diarrhea
Serious Anaphylaxis
Postmarketing Abdominal pain, rash
Pharmacology
C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that inactivates key proteases in the complement, fibrinolytic, and coagulation systems -- including C1r, C1s, factor XIIa, and plasma kallikrein -- thereby preventing bradykinin generation and reducing vascular permeability; HAEGARDA replaces the missing or malfunctioning C1-INH protein in HAE patients.
Recombinant C1 esterase inhibitor (C1INH) that regulates the complement and contact system pathways by irreversibly binding target proteases (activated C1s, kallikrein, factor XIIa, factor XIa), restoring functional C1INH activity and suppressing the bradykinin-mediated vascular permeability increases that underlie HAE attacks.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Haegarda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
Ruconest
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Haegarda
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Ruconest
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Haegarda
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Ruconest
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HaegardaView full Haegarda profile
RuconestView full Ruconest profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.